Tag: Glembatumumab vedotin

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Glembatumumab vedotin

Celldex Therapeutics, Inc. (CLDX) Receives Consensus Rating of “Hold” from Brokerages

Added to Collection on: 2019-03-17 00:30:00

Tags for this article:

Biotechnology
Specialty drugs
Monoclonal antibodies
Biopharmaceutical
Life Sciences
Varlilumab
Glembatumumab vedotin
Celldex Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
Acadian Asset Management LLC Purchases 287281 Shares of Celldex Therapeutics, Inc. (CLDX)

Added to Collection on: 2019-03-16 18:30:00

Tags for this article:

Medicine
Clinical medicine
Stock
Monoclonal antibodies
Drugs
Varlilumab
Glembatumumab vedotin
Celldex Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Telemetry Investments LLC

Added to Collection on: 2019-03-22 23:22:30

Tags for this article:

Medicine
Clinical medicine
Monoclonal antibodies
Drugs
Varlilumab
Glembatumumab vedotin
Celldex Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
Acadian Asset Management LLC Acquires 287281 Shares of Celldex Therapeutics, Inc. (CLDX)

Added to Collection on: 2019-03-24 12:30:00

Tags for this article:

Medicine
Clinical medicine
Stock
Monoclonal antibodies
Drugs
Varlilumab
Glembatumumab vedotin
Celldex Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
Celldex Therapeutics (CLDX) Downgraded by ValuEngine

Added to Collection on: 2019-03-26 18:05:11

Tags for this article:

Medicine
Clinical medicine
Monoclonal antibodies
Drugs
Varlilumab
Glembatumumab vedotin
Celldex Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
Celldex Therapeutics (NASDAQ:CLDX) Posts Quarterly Earnings Results, Beats Estimates By ...

Added to Collection on: 2019-03-31 13:15:00

Tags for this article:

Medicine
Clinical medicine
Stock
Monoclonal antibodies
Drugs
Varlilumab
Glembatumumab vedotin
Celldex Therapeutics

Click the tags to see associated articles and topics

View Article Details
$-0.28 EPS Expected for Seattle Genetics, Inc. (SGEN); Ativo Capital Management Has Decreased ...

Added to Collection on: 2019-04-08 01:20:30

Tags for this article:

Clinical medicine
NASDAQ
Biotechnology
TSMC
Monoclonal antibodies
Ativo Capital Management LLC
Seattle Genetics
Drugs
Team SoloMid
Glembatumumab vedotin
Brentuximab vedotin
Antibody-drug conjugates
Vadastuximab talirine
S&P 500 INDEX - CBOE
Abu Dhabi SE Industrial Index

Click the tags to see associated articles and topics

View Article Details
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results

Added to Collection on: 2021-03-29 19:52:30

Tags for this article:

CDX
Glembatumumab vedotin
Celldex Therapeutics Inc.

Click the tags to see associated articles and topics

View Article Details
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of

Added to Collection on: 2022-10-10 11:05:34

Tags for this article:

Clinical medicine
Cancer treatments
Medicine
Antineoplastic drugs
Breast cancer
Triple-negative breast cancer
Protein kinase inhibitors
Chemotherapy
Targeted therapy
Glembatumumab vedotin
Bemcentinib

Click the tags to see associated articles and topics

View Article Details
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of ... - BioSpace

Added to Collection on: 2022-10-10 10:53:27

Tags for this article:

Clinical medicine
Medicine
Cancer treatments
Antineoplastic drugs
Breast cancer
Triple-negative breast cancer
Protein kinase inhibitors
Chemotherapy
Targeted therapy
Glembatumumab vedotin
Bemcentinib

Click the tags to see associated articles and topics

View Article Details